396 related articles for article (PubMed ID: 11353053)
1. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
2. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
3. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
Bahnassy AA; Zekri AR; Abdallah S; El-Shehaby AM; Sherif GM
Pathol Int; 2005 Feb; 55(2):53-62. PubMed ID: 15693850
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.
Osman I; Drobnjak M; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 Aug; 5(8):2082-8. PubMed ID: 10473090
[TBL] [Abstract][Full Text] [Related]
6. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
7. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3.
Lin J; Tang H; Jin X; Jia G; Hsieh JT
Oncogene; 2002 May; 21(19):3082-8. PubMed ID: 12082540
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
9. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas.
Ittmann M; Wieczorek R; Heller P; Dave A; Provet J; Krolewski J
Am J Pathol; 1994 Aug; 145(2):287-93. PubMed ID: 8053489
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.
Koga T; Hashimoto S; Sugio K; Yoshino I; Nakagawa K; Yonemitsu Y; Sugimachi K; Sueishi K
Int J Cancer; 2001 Jul; 95(4):232-9. PubMed ID: 11400116
[TBL] [Abstract][Full Text] [Related]
11. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
[TBL] [Abstract][Full Text] [Related]
12. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
[TBL] [Abstract][Full Text] [Related]
13. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
14. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
[TBL] [Abstract][Full Text] [Related]
15. The MDM2 oncoprotein promotes apoptosis in p53-deficient human medullary thyroid carcinoma cells.
Dilla T; Velasco JA; Medina DL; González-Palacios JF; Santisteban P
Endocrinology; 2000 Jan; 141(1):420-9. PubMed ID: 10614665
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
18. Association of p53 mutations with metastatic prostate cancer.
Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
[TBL] [Abstract][Full Text] [Related]
19. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
